Citations

Clear

187 citation(s) found for "Ha, Gavin".

A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).
Karp, Daniel D. , Wright, Gavin, Johnson, D. H., Johnston, M. R., Goodman, Gary E. , Clamon, G. H., Okawara, G. S., Marks, R., Ruckdeschel, John C. , Lee, S. J., Wright, G. L. Shaw

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 28 | Issue: 18_suppl | Pages: CRA7004-CRA7004

10.1200/jco.2010.28.18_suppl.cra7004 Get It

CRA7004 Background: Selenium was reported to have possible lung cancer chemopreventive benefits based on a large skin cancer trial secondary observation. (JAMA 1996; 276: 1957-1963). Since that time, research continued to suggest that Se could decrease risk of second primary tumor (SPT) in persons with resected NSCLC. In 2007, a publication from another group suggested an increased association of Se with type 2 diabetes (Annals Int Med 147:217-223). Methods: From Oct 2000-Nov 2009, 6 groups, led by ECOG, carried out a double blind, placebo controlled trial using selenized yeast 200 micrograms daily in a 2:1 randomization vs. placebo for 48 mo in completely resected stage I NSCLC. Participation was 6–36 mo post-op and required a negative mediastinal node biopsy, no excessive vitamin intake, normal liver function, a negative chest x-ray, and no other evidence of recurrence. Planned size of 1,960 participants had been designed to detect a 40% decrease in SPTs with 80% power. Methylation studies of sputum and blood (S. Belinsky) add important biologic correlates to this project. Results: Interim analysis occurred in Oct 2009 after 1,561/1,772 pts reached step 2 (completion of the 4 week (step 1) run-in period requiring at least 75% of the study drug to be taken). Endpoints included SPTs, recurrence, and toxicity. A total of 216 SPTs developed of which 84 (38.9%) were lung cancer. SPT (lung/overall) incidence was 1.36/3.66 per 100 person yrs for placebo vs. 1.91/4.11 for Se (p=.150). 5 yr progression free survival was 78% for placebo vs. 72% for Se. Study was stopped according to futility analysis. Grade 1 or 2 toxicity occurred in 38% of placebo and 39% Se. Grade 3 toxicity was 3% placebo vs. <1% Se. Compliance was excellent (>95% at 2 yrs). Conclusions: No increase in diabetes mellitus or skin cancer was detected. Se was safe but conferred no benefit over placebo. Methylation studies are continuing. [Table: see text]
Gastrointestinal stromal tumour in neurofibromatosis 1: 18F FDG PET/CT imaging
Sugrue, Gavin , Nguyen, Ba D.

Mayo Clinic

BMJ Case Reports | August 16, 2016 | Volume: 2016 | Issue: No issue available | Pages: bcr2016217038

10.1136/bcr-2016-217038 | PMID 27530882 Get It

Central retinal vein occlusion after plateletpheresis
Roddy, Gavin W. , Kreuter, Justin D. , Koh, Brian D. , Barkmeier, Andrew J.

Mayo Clinic

Transfusion | June 6, 2016 | Volume: 56 | Issue: 6 | Pages: 1258-1258

10.1111/trf.13419 | PMID 27264010 Get It

PTU-061 Utility of endoscopic retrograde cholangiography to diagnose IgG4-associated cholangitis: an international, double blind, randomised, multicentre study
Johnson, Gavin , Levy, Michael J. , Kamisawa, Terumi , Baron, Todd H. , Topazian, Mark , Okazaki, Kazuichi , Egawa, Naoto, Sheikh, Kashif, Amin, Z. , Shimosegawa, Tooru , Sandanayake, N S, Church, Nicholas , Chapman, Michael H. , Hatfield, A R, Pereira, Stephen P. , Webster, George, Kalaitzakis, Emmanouil , Levy, Michael J. , Takahashi, Naoki , Kanno, Atsushi , Uchida, Kazushige , Sandanayake, Neomal S., Chari, Suresh T.

Mayo Clinic

Liver I posters | January 7, 2016 | Volume: No volume available | Issue: No issue available | Pages: A73.2-A73

10.1136/gut.2009.209056u Get It

Reply to P.G. Gavin et al
Perez, Edith A. , Thompson, E. Aubrey , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | August 18, 2015 | Volume: 33 | Issue: 31 | Pages: 3672-3673

10.1200/jco.2015.62.6051 | PMID 26282664 Get It

PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data
Hart, Steven N. , Moore, Raymond M. , Zimmermann, Michael T. , Oliver, Gavin R. , Egan, Jan B. , Bryce, Alan H. , Kocher, Jean-Pierre A., Bryce, Alan H , Hart, Steven N , Zimmermann, Michael T , Moore, Raymond

Mayo Clinic

PeerJ | May 19, 2015 | Volume: 3 | Issue: No issue available | Pages: e970

10.7717/peerj.970 | PMID 26038725 Get It

Abstract 1894: Extensive genomic profiling of a rare extranodal-follicular dendritic cell sarcoma: Implications for future individualized therapy
Starr, Jason S. , Attia, Steven , Wang, Xue , Necela, Brian M. , John, Casler, Menke, David M. , Sarangi, Vivek, Copland, John A. , Parker, Alexander A., Thompson, E. Aubrey, Smallridge, Robert C., Asmann, Yan W. , Davila, Jaime , Wang, Chen , Oliver, Gavin R. , Joseph, Richard W. , Parker, Alexander

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 1894-1894

10.1158/1538-7445.am2014-1894 Get It

Abstract Background: Extranodal follicular dendritic cell sarcoma (FDCS) is an exceedingly rare tumor type that is limited to few cases in the literature. Given the rarity of this tumor, there is a lack of genetic understanding of this disease resulting in a non-individualized plan of care for patients with this disease. Herein, we are the first to describe extensively molecularly the DNA and RNA of this tumor. Methods: Under an IRB approved protocol, the patient's tumor and whole blood was freshly frozen for molecular analysis. We performed Next Generation Sequencing (NGS) genomic profiling including exome capture, mate pair and mRNA sequencing on this tumor. Exome and mRNA data were processed through Mayo's Bioinformatics Core standard pipelines, GENOME GPS 1.2.1 and MAPRSeq v1.2.1. Mutations and indels were prioritized depending on whether or not they belonged to known cancer associated genes. Copy number variations (CNVs) in Exome and Mate Pair data was found through PatternCNV v 1.0.1 and fusion transcripts were found using SNOWSHOES-FTD and Tophat-Fusion 2.0.6. Results: At the genomic level large scale genomic rearrangements were detected, including chr19 and chr20 trisomy, chr15q and chr17q segmental duplications result in two intra-chromosomal fusion genes, and translocations leading to four inter-chromosomal fusion genes between chr15 and chr17. Of particular interest is a stop codon gain in the CLTC1 (chr22) gene, which is involved in the mitotic spindle organization which has been associated with meningiomas and breast tumorigenesis. The new stop codon is before the site required for the recruitment of the proteins to the spindle. The large scale genomic rearrangement described above is consistent with this defective spindle assembly hypothesis. Another intriguing mutation detected in the VEGFR1 (chr13) gene leads to a 45% mis-spliced transcript. VEGFR1 is thought to modulate VEGFR2 which plays an essential role in angiogenesis, by acting as a decoy receptor. Therefore the loss of function of VEGFR1 might lead to hyper-activity of VEGFR2 pathway and a potential therapeutic strategy is to directly inhibit the VEGFR2 pathway. Furthermore missense mutations in the ATM (chr11) and TP53 (chr17) genes were found. PARP inhibitors have been used with success for cancer with defects in the ATM gene. Finally a novel fusion transcript of HDGRFP3 (chr15) and SHC4 (chr15) was identified. Such fusion results in an overexpressed SHC4 gene which has been associated with metastatic melanomas. Conclusions: In summary, genomic profiling of a rare thyroid FDCS identified drug targetable genes as well as changes related to tumor etiology. Future work is necessary to determine the functional significance of these molecular findings and whether they will predict benefit to targeted therapies. Citation Format: Jaime I. Davila, Jason Starr, Steven Attia, Chen Wang, Xue Wang, Brian Necela, Casler John, David Menke, Vivek Sarangi, Gavin Oliver, Richard Joseph, John Copland, Alexander Parker, E. Aubrey Thompson, Robert Smallridge, Yan W. Asmann. Extensive genomic profiling of a rare extranodal-follicular dendritic cell sarcoma: Implications for future individualized therapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1894. doi:10.1158/1538-7445.AM2014-1894
Reliability of magnetic resonance elastography using multislice two‐dimensional spin‐echo echo‐planar imaging (SE‐EPI) and three‐dimensional inversion reconstruction for assessing renal stiffness
Low, Gavin , Owen, Nicola , Joubert, Ilse , Patterson, Andrew J. , Graves, Martin J. , Glaser, Kevin J. , Alexander, Graeme , Lomas, David J.

Mayo Clinic

Journal of Magnetic Resonance Imaging | December 24, 2014 | Volume: 42 | Issue: 3 | Pages: 844-850

10.1002/jmri.24826 | PMID 25537823 Get It

BackgroundTo evaluate the reliability of MRE using a spin‐echo echo‐planar imaging (SE‐EPI) renal MRE technique in healthy volunteers.MethodsInstitutional review board approved prospective study in which all participants provided written informed consent. Sixteen healthy volunteers comprising seven males and nine females with a median age of 35 years (age range: 23 to 59 years) were included. Coronal 90 Hz and 60 Hz MRE acquisitions were performed twice within a 30‐min interval between examinations. Renal MRE reliability was assessed by (i) test–retest repeatability, and (ii) inter‐rater agreement between two independent readers. The MRE‐measured averaged renal stiffness values were evaluated using: intraclass correlation coefficient (ICC), Bland‐Altman and the within‐subject coefficient of variation (COV).ResultsFor test–retest repeatability, Bland‐Altman showed a mean stiffness difference between examinations of 0.07 kPa (95% limits of agreement: −1.41, 1.54) at 90 Hz and 0.01 kPa (95% limits of agreement: −0.51, 0.53) at 60 Hz. Coefficient of repeatability was 1.47 kPa and 0.52 kPa at 90 Hz and 60 Hz, respectively. The within‐subject COV was 13.6% and 7.7% at 90 Hz and 60 Hz, respectively. ICC values were 0.922 and 0.907 for test–retest repeatability and 0.998 and 0.989 for inter‐rater agreement, respectively (P < 0.001).ConclusionSE‐EPI renal MRE is a reliable technique. J. Magn. Reson. Imaging 2015;42:844–850.